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Background and objective: Plasma B-type natriuretic peptide (BNP) levels are deter-
mined by several factors. The presence of atrial ﬁbrillation (AF) is one of these
factors. Meanwhile, plasma BNP levels are well correlated with left ventricular (LV)
ﬁlling pressure in patients with sinus rhythm. Furthermore, LV ﬁlling pressure can be
estimated by the ratio of early diastolic transmitral velocity to early diastolic mitral
annular velocity (E/e′ ratio) in patients with sinus rhythm or with AF. However, it
is still unclear if elevated plasma BNP levels reﬂect increases in LV ﬁlling pressure
in patients with AF, especially with preserved LV systolic function. This study was
designed to examine which factors determine plasma BNP levels in patients with
persistent nonvalvular AF and preserved LV systolic function.
Methods and results: We examined 195 clinically stable outpatients with persistent
nonvalvular AF and preserved LV systolic function. They underwent comprehensive
2-dimensional and Doppler echocardiography, plasma BNP and creatinine levels, clin-
ical history, and heart rate were determined. Then we statistically analyzed the
′correlation between plasma BNP levels and several variables including E/e ratio.
On univariate analyses, plasma BNP levels were signiﬁcantly correlated with age,
LV diastolic diameter (LVDd), E/e′ ratio, and mitral E wave deceleration time. In
addition, plasma BNP levels were signiﬁcantly higher in males and in patients with a
history of congestive heart failure and those who had been administered a -blocker.
On multiple linear regression analyses, E/e′ ratio, age, LVDd, and administration of
-blocker were independent determinant factors of plasma BNP levels.
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Conclusions: Plasma BNP levels in patients with persistent AF and preserved LV systolic
function are affected by E/e′ ratio, age, LVDd, and administration of -blockers.




















































































Continuous variables are presented as mean
value± SD and categorical variables as numbers© 2009 Japanese Colleg
reserved.
ntroduction
lasma B-type natriuretic peptide (BNP) is released
y cardiomyocytes in response to increased ventric-
lar wall stress. It is known that plasma BNP levels
re well correlated with left ventricular (LV) ﬁll-
ng pressure in patients with sinus rhythm [1,2].
owever, it is still unclear if plasma BNP level can
stimate LV ﬁlling pressure in patients with atrial
brillation (AF). Plasma BNP levels are also affected
y several factors other than LV ﬁlling pressure,
uch as age, renal function, and the presence of
ongestive heart failure (CHF) and acute coronary
yndrome. The presence of AF and LV systolic dys-
unction are two of these factors. In several studies,
t has been reported that plasma BNP levels tend to
e higher in patients with AF than in patients with
inus rhythm, but vary widely [3—6]. LV systolic dys-
unction is also known to elevate plasma BNP levels
7]. On the other hand, the ratio of early diastolic
ransmitral velocity to early diastolic mitral annular
elocity (E/e′ ratio) can predict LV ﬁlling pressure
hether in patients with sinus rhythm [2,8—10] or
F [11]. Thus, E/e′ ratio can be used as a surrogate
arker that reﬂects LV ﬁlling pressure in patients
ot only with sinus rhythm but also with AF. There-
ore, we examined the correlation between plasma
NP level and several variables including echocar-
iographic indexes such as E/e′ ratio in patients
ith persistent nonvalvular AF and preserved LV
ystolic function to assess whether the higher BNP
evels in those patients reﬂect elevated LV ﬁlling
ressure.
ethods
he investigational protocol was approved by the
nstitutional review boards, and all patients gave
ritten informed consent before participation.
We examined 195 clinically stable outpatients
male/female: 143/52; average age 71.7 years)
ith persistent nonvalvular AF and preserved LV
ystolic function at our institution. They were in
clinically stable state and had no or only mild
HF symptoms (New York Heart Association func-
ional class I or II). Exclusion criteria were low LV
jection fraction (LVEF) (<40%), congenital heart




iunction, and severe valvular heart disease. These
atients underwent comprehensive 2-dimensional
nd Doppler echocardiography, plasma BNP and cre-
tinine level and heart rate measurements, and
linical history taking.
Echocardiographic measurements were per-
ormed with a commercially available echocardio-
raphic machine (Vivid 7, GE Vingmed Ultrasound,
orten, Norway or SONOS 7500, Philips, Andover,
A, USA). A complete echocardiographic study was
erformed using standard views and techniques.
VEF was measured using Teichholz method. E/e′
atio and mitral E wave deceleration time (E-DcT)
ere averaged over 5 cardiac cycles. We used only
eptal E/e′ ratio measured in the apical 4 cham-
er view for this study. Heart rate of each patient
t the time of echocardiographic measurement was
imultaneously recorded.
After 30min of supine rest, a blood sample
as collected from each patient. Then, 7ml of
lood was put into a tube containing ethylenedi-
minetetraacetic acid and the plasma BNP level
as immediately measured using the TOSOH II
est (TOSOH AIA Inc., Osaka, Japan). At the
ame time, 10ml of blood was centrifuged at
500× g for 10min. Then, the plasma creatinine
evel was immediately measured by enzymatic
ethod using the Cre-II reagent (Kainos Inc., Tokyo,
apan).
tatistical analysis
e analyzed the correlation between plasma
NP levels and several variables, such as age,
ender, heart rate, LVEF, LV diastolic diameter
LVDd), intraventricular septal thickness (IVST),
eft atrial diameter (LAD), E/e′ ratio, E-DcT,
he plasma creatinine level, history of hyper-
ension, hyperlipidemia, diabetes mellitus, CHF
nd myocardial infarction, and administration of
ngiotensin-converting enzyme (ACE) inhibitor or
ngiotensin receptor blocker (ARB), -blocker, dig-percent). Natural log transformation was per-
ormed on BNP values due to nonlinear distribution.
e used simple linear regression analyses to exam-
ne the relationship between plasma BNP levels and
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Table 1 Clinical characteristics.
r p-Value on
univariate analysis
p-Value on multiple linear
regression analysis
Age (years) 71.7± 8.6 0.21 0.0026 0.027
Gender (male) 143 (73%) — 0.011 0.96
History
Hypertension 110 (56%) — 0.15 —
Hyperlipidemia 91 (47%) — 0.099 —
Diabetes mellitus 35 (18%) — 0.53 —
Congestive heart failure 51 (26%) — 0.0088 —
Myocardial infarction 10 (5%) — 0.36 —
Administration
-Blocker 85 (44%) — 0.0015 <0.001
ACE inhibitor or ARB 107 (55%) — 0.93 —
Digitalis 90 (46%) — 0.67 —













eACE, angiotensin-converting enzyme; ARB, angiotensin recepte
continuous variables such as age, heart rate, LVEF,
LVDd, IVST, LAD, E/e′ ratio, E-DcT and the plasma
creatinine level. We performed group comparisons
of plasma BNP levels by means of t-test if vari-
ables were normally distributed and by means of
Mann—Whitney U test if the data were not normally
distributed for categorical variables such as gender,
history of hypertension, hyperlipidemia, diabetes
mellitus, congestive heart failure, and myocardial
infarction, and administration of ACE inhibitor or
ARB, -blocker, digitalis and diuretic. Then, we per-
formed multiple linear regression analyses using
only variables whose p values were less than 0.20 on
univariate analyses. A value of p < 0.05 was consid-
ered statistically signiﬁcant. All statistical analyses
were performed with Stat ﬂex ver. 5.0 for windows




Table 2 Blood sampling data, echocardiographic indexes,
r p
u
BNP 163.6± 106.3 (pg/ml) —
HR 74.5± 14.0 (min−1) −0.01
LVEF 68.9± 10.8 (%) 0.081
LVDd 48.8± 5.6 (mm) −0.24 <
IVST 9.9± 1.8 (mm) 0.04
LAD 47.4± 6.0 (mm) 0.052
E/e′ 13.3± 5.7 0.2
E-DcT 191.5± 45.7 (ms) −0.14
Creatinine 0.91± 0.23 (mg/dl) −0.004
BNP, B-type natriuretic peptide; E-DcT, E wave deceleration time
to early diastolic mitral annular velocity; LVEF, left ventricular ej
thickness; LAD, left atrial diameter; LVDd, left ventricular diastoliccker.
esults
he clinical characteristics of 195 patients are
isted in Table 1. Of the 195 patients with persistent
onvalvular AF and preserved LV systolic function,
10 patients had hypertension, 91 patients had
yperlipidemia, 35 patients had diabetes mellitus,
1 patients had a history of CHF, and 10 patients had
history of myocardial infarction. Then, -blockers
ere administered to 85 patients, ACE inhibitors
r ARBs to 107 patients, digitalis to 90 patients,
nd diuretics to 50 patients. Blood sampling data,
chocardiographic indexes and heart rate are dis-
layed in Table 2.
On simple linear regression analyses, Log trans-
ormed plasma BNP levels (LnBNP) was positively















; E/e′ ratio, the ratio of early diastolic transmitral velocity
ection fraction; HR, heart rate; IVST, intraventricular septal
diameter.







































Digure 1 Linear regression between LnBNP and (a) E/e
eptide; E/e′ ratio, the ratio of early diastolic transmitr
og transformed plasma BNP levels; LVDd, left ventricular
atio (r = 0.20, p = 0.0046), and negatively corre-
ated with LVDd (r =−0.24, p < 0.001) and E-DcT
r =−0.14, p = 0.047). These linear regression lines
re displayed in Fig. 1. The plasma BNP level
as signiﬁcantly higher in males (p = 0.011) and
n patients with a history of CHF (p = 0.0088) and
hose who had been administered a -blocker
p = 0.0015). These results on univariate analy-
es are listed in Tables 1 and 2. On multiple
inear regression analyses, age (p = 0.027), LVDd
p = 0.015), E/e′ (p = 0.036), and administration of
-blocker (p < 0.001) were signiﬁcantly correlated
ith LnBNP. E-DcT showed a tendency to correlate
ith the plasma BNP level (p = 0.054). These results
re also displayed in Tables 1 and 2.
Because it is known that E/e′ ratio >15 can pre-
ict LV ﬁlling pressure increase [2,9,12] in patients
ith sinus rhythm and that E/e′ ratio >15 is an inde-
endent predictor of mortality and CHF in patients
ith nonvalvular AF [13], we drew the receiver
perating characteristic (ROC) curve for plasma
NP level to predict E/e′ ratio >15 (Fig. 2). The





Aio, (b) age, (c) LVDd, (d) E-DcT. BNP, B-type natriuretic
locity to early diastolic mitral annular velocity; LnBNP,
stolic diameter; E-DcT, mitral E wave deceleration time.
sensitivity 57%, speciﬁcity 61%, AUC= 0.63). The
edian age of patients without administration of -
locker was 75 years. Because plasma BNP level was
ffected by age and administration of -blocker, we
elected patients less than 75 years old and without
dministration of -blocker and drew the ROC curve
or plasma BNP level to predict E/e′ ratio >15. The
ptimal cutoff level was also 147 pg/ml (sensitivity
7.5%, speciﬁcity 89.1%, AUC= 0.88).
On the other hand, the optimal cutoff age
nd LVDd to predict plasma BNP level >147 pg/ml
ere 73 years (sensitivity 61.6%, speciﬁcity 60.6%,
UC = 0.60) and 48.8mm (sensitivity 62.8%, speci-
city 56.9%, AUC= 0.63), respectively.
iscussionhis study demonstrates that the plasma BNP level
s positively correlated with age, E/e′ ratio, admin-
stration of -blocker, and negatively correlated
ith LVDd in patients with persistent nonvalvular
F and preserved LV systolic function.
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Figure 2 The ROC curve for plasma BNP level to predict E/e′ ratio >15. The optimal plasma BNP cutoff level was































ldiastolic transmitral velocity to early diastolic mitral an
curve.
Several studies showed that plasma BNP lev-
els are well correlated with LV ﬁlling pressure
in patients with sinus rhythm [1,2]. However, in
patients with AF, the correlation between plasma
BNP levels and LV ﬁlling pressure is unclear. On the
other hand, E/e′ ratio on echocardiographic study
can predict LV ﬁlling pressure in patients not only
with sinus rhythm but also with AF [2,8—11,14].
Thus, E/e′ ratio can be used as a surrogate marker
that reﬂects LV ﬁlling pressure in patients not only
with sinus rhythm but also with AF. In our study,
E/e′ ratio was signiﬁcantly correlated with the
plasma BNP level. This result suggests that even in
patients with persistent AF and preserved LV sys-
tolic function, the plasma BNP level may predict
LV ﬁlling pressure. There are only two small stud-
ies that examined the correlation between plasma
BNP levels and E/e′ ratio in patients with AF [3,14].
Therefore, this is the largest study analyzing the
correlation between plasma BNP levels and E/e′
ratio in patients with AF. One of these studies
reported that plasma BNP levels signiﬁcantly cor-
related with E/e′ ratio in patients with AF [3].
Exclusion criteria in that study were about the same
as ours. Although the number of patients with AF in
that study was 49 and much fewer than our study,
the result in that study supports and corresponds to
our result. Another study reported that plasma BNP
levels did not have any correlation with E/e′ ratio
in patients with AF and preserved LV systolic func-
tion [14]. This result conﬂicts with our result, but
the population in that study included symptomatic
heart failure. In our study, subjects were clinically
stable outpatients, and New York Heart Association




cr velocity; ROC curve, receiver operating characteristic
Some studies showed that plasma BNP levels had
prognostic value of mortality and morbidity in
inus rhythm [15—18]. On the other hand, it is
eported that E/e′ ratio >15 can predict mortal-
ty and CHF in patients with AF [13]. According to
he ROC curve for plasma BNP level to predict E/e′
atio >15, the plasma BNP level (BNP > 147 pg/ml)
an predict adverse outcomes with a sensitivity
7% and a speciﬁcity 61% in patients with stable
ersistent nonvalvular AF and preserved LV sys-
olic function; the cutoff value is especially useful
n younger patients (<75 years) without adminis-
ration of -blocker with a sensitivity 87.5% and
speciﬁcity 89.1%. So it may be preferable to
ay more attention to that speciﬁc population.
n addition, to take this measurement, a special
chocardiographic machine and a trained techni-
ian to examine the E/e′ ratio is required. On the
ther hand, plasma BNP level measurement is rel-
tively easy. So we think that the plasma BNP level
ay be a limited but easier predictor of adverse
utcomes in patients with persistent nonvalvular AF
nd preserved LV systolic function, as compared to
/e′ ratio, in the clinical setting. In some studies,
t has been reported that E-DcT can also predict LV
lling pressure in patients with AF [19,20]. On the
ther hand, it has also been reported that E-DcT has
o correlation with LV ﬁlling pressure in AF patients,
specially those with preserved EF [3,11,14,21]. In
ur study, E-DcT correlated with the plasma BNP
evel on simple linear regression analysis, but not
n multiple linear regression analysis. The reason
or this result may be that our study did not include
atients with low LVEF. Age also had a signiﬁcant


















































[eterminant factors of BNP in patients with AF
orresponds to a previous report that age is an
mportant factor that affects plasma BNP levels
22,23]. Administration of -blocker signiﬁcantly
orrelated with the plasma BNP level. This reason
s unclear, but it is presumable that -blockers tend
o be administered to patients whose plasma BNP
evels are high.
Finally, LVDd was also a signiﬁcant variable that
orrelated negatively with the plasma BNP level.
he reason for this correlation is also unclear.
owever, this study excluded patients with LV dys-
unction and severe valvular heart disease. So LV
ysfunction with LV dilatation that tends to elevate
lasma BNP levels such as dilated cardiomyopathy,
schemic cardiomyopathy, and valvular cardiomy-
pathy were also excluded. Indeed, in this study,
ean LVDd was 48.8± 5.6mm and patients with
xtremely high LVDd did not exist. Moreover,
VDd of patients with a history of hypertension
s smaller than that of patients without a history
f hypertension (data not shown). So, it is possi-
le that, in this population, because patients with
maller LVDd tend to have diastolic dysfunction,
VDd correlated negatively with the plasma BNP
evel.
tudy limitation
irst, we did not perform the invasive evaluation
f LV ﬁlling pressure. Therefore, our results regard-
ng the correlation between the plasma BNP level
nd LV ﬁlling pressure depends on the correlation
etween E/e′ ratio and LV ﬁlling pressure. Second,
e used only septal E/e′ for this study, although
ost of the patients in this study do not have wall
otion abnormality. Thirdly, because we did not
easure LV end-diastolic volume and LA volume
ndex, our assessment for LA and LV dimension may
e less accurate.
onclusions
lasma BNP levels were signiﬁcantly correlated
ith age, E/e′ ratio, LVDd, and administration of -
locker in patients with persistent nonvalvular AF
nd preserved LV systolic function, and may be a
linically useful marker in those patients, especially
n patients who are less than 75 years old and have
ot been administered -blockers.eferences
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